Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 4
3 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Functional axon regeneration using autologous bulbar olfactory ensheathing cells and spinal cord bridging in complete spinal cord injury
Spinal Cord Injury at C5-Th10 Level With Complete Lesion · Spinal Cord Transection
Enrolment: 2 · Results not recorded
Transplantation of autologous olfactory ensheathing cells for treatment of complete human spinal cord injuries
Complete Spinal Cord Injuries
Enrolment: 10 · Results not recorded
Collection and characterisation of human olfactory ensheathing cells
Spinal Cord Injury
Enrolment: 50 · Results not recorded
Safety and feasibility of intracerebral implantation of olfactory ensheathing cells in old stroke patients
Infarction, Middle Cerebral Artery · Ischemic Stroke
Enrolment: 6 · Results not recorded
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatSpinal cord injuryComplete transectionWistarMaleTransplantation of tissue pieces into the lesion siteAcute, 2 weeks or 4 weeks after injury
Model: Complete spinal cord transection
Both graft types produced only discrete and comparable hindlimb improvement with similar tissue sparing and sprouting, acute grafting fostered limited supraspinal regeneration, and no differences were found between acute, 2 week or 4 week delayed transplantation, suggesting the effects were not att…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.72. Machine-extracted fields require source verification.